Rikke Sørensen

Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction.

The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs (NSAIDs) have been associated with increased cardiovascular risk, but the risk in patients with established cardiovascular disease is unknown. In the present study, we analyzed the risk of rehospitalization for acute myocardial infarction (re-MI) and death related to the use of NSAIDs including selective COX-2 inhibitors in patients with a prior myocardial infarction (MI). We included 58,432 patients discharged alive after a first MI, and subsequent use of all NSAIDs was identified from a nationwide register of drug dispensing from pharmacies. We found a dose-dependent increase in risk of death for both the selective COX-2 inhibitors and the nonselective NSAIDs (all of the drugs tested). There were trends for increased risk of re-MI associated with the use of both the selective COX-2 inhibitors and the nonselective NSAIDs (high dosages). Selective COX-2 inhibitors in all dosages and nonselective NSAIDs in high dosages should be used with particular caution in patients with a prior MI.

Second generation drug‐eluting stents versus bare‐metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET‐PROVE I and II trials

To compare mid‐term outcomes between patients undergoing proximal left anterior descending artery (LAD) percutaneous coronary intervention (PCI) with second generation drug‐eluting stent (DES) or bare‐metal stent (BMS).

TCT-312 Increased Cardiac Death and Stent Thrombosis in Chronic Obstructive Pulmonary Disease Patients Undergoing Percutaneous Coronary Intervention. An analysis of the BASKET-PROVE I and II trials

nos: 312 357 TCT-312 Increased Cardiac Death and Stent Thrombosis in Chronic Obstructive Pulmonary Disease Patients Undergoing Percutaneous Coronary Intervention. An analysis of the BASKET-PROVE I and II trials Tannas Jatene, Tor Biering-Sørensen, Kotaro Nochioka, Fernanda Mangione, Kim Hansen, Rikke Sørensen, Jan Skov Jensen, Peter Jørgensen, Raban Jeger, Christoph Kaiser, Matthias Pfisterer, Soeren Galatius Brigham and Women’s Hospital, Boston, Massachusetts, United States; Department of Cardiology, 2nd Medical School, Charles University and Motol University Hospital, Prague, Czech Republic; University of Texas Health Science Center at San Antonio; Beneficência Portuguesa de São Paulo Hospital, Boston, Massachusetts, United States; Department of Cardiology, 2nd Medical School, Charles University and Motol University Hospital, Prague, Czech Republic; Herlev & Gentofte Hospital, University of Copenhagen, Denmark; Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark; Emory University School of Medicine; Emory University School of Medicine; University Hospital Basel, Basel, Switzerland; University Hospital, Basel, Switzerland; Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark BACKGROUND COPD is associated with long-term all-cause death following PCI with bare-metal stents (BMS). Regarding other outcomes previous studies have shown conflicting results and the impact of drug-eluting stent (DES) in this population is not well known. We sought to evaluate the impact of chronic obstructive pulmonary disease (COPD) on percutaneous coronary intervention (PCI) outcomes, and the interaction with stent type. METHODS We analyzed 4605 patients that underwent PCI with BMS (33.1%) or DES (66.9%) from the BASKET-PROVE trials I and II. RESULTS COPD patients (n1⁄4283, 6.1%), were older and had more frequently a smoking or cardiovascular event history. At 2-year follow-up, cumulative event rates for patients with versus without COPD were the following: major adverse cardiac events [MACE: composite of cardiac death, non-fatal myocardial infarction (MI) and target vessel revascularization]: 15.2 vs. 8.1% (p<0.001); all-cause death: 11.7 vs. 2.4%, (p<0.001); cardiac death: 5.7 vs. 1.2%, (p<0.001); MI: 3.5 vs. 1.9% (p1⁄40.045); definite/probable/possible stent thrombosis: 2.5 vs. 0.9% (p1⁄40.01); and major bleeding: 4.2 vs. 2.1% (p1⁄40.014). After adjusting for confounders including smoking status, COPD remained an independent predictor for MACE (HR 1.80, 95%CI 1.31-2.49), all-cause death (HR 3.62, 95%CI 2.41-5.45), cardiac death (HR 3.12, 95%CI 1.74-5.60) and stent thrombosis (HR 2.39, 95% CI 1.035.54). We did not find evidence of an interaction between COPD and DES implantation (P for interaction 1⁄4 0.29). Model 1 Model 2